Skip to Content

Kodiak Sciences Inc KOD

Rating as of

Morningstar’s Analysis

Valuation
Currency in USD
Is it the right time to buy or sell?
Find out with Morningstar Premium
Is it the right time to buy or sell?
Find out with Morningstar Premium

1-Star Price

PREMIUM

5-Star Price

PREMIUM

Economic Moat

PREMIUM

About Quantitative Ratings

Morningstar Quantitative ratings for equities (denoted on this page by) are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies withratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating. Click here for more on how to use these ratings.

Company Profile

Business Description

Kodiak Sciences Inc is a clinical-stage company. It is engaged in developing innovative therapeutics to treat the high prevalence of ophthalmic diseases. The most advanced product candidate of the group is KSI-301, a biologic therapy built with an antibody biopolymer conjugate platform, which is designed to maintain potent and effective drug levels in ocular tissue.

Contact
1200 Page Mill Road
Palo Alto, CA, 94304
T +1 650 281-0850
Sector Healthcare
Industry Biotechnology
Most Recent Earnings Dec 31, 2020
Fiscal Year End Dec 31, 2021
Stock Type Distressed
Employees 72